ST6GAL1 and prostate cancer: Together, our data suggests that levels of both ST6GAL1 and larger branched α2-6 sialylated tri-antennary and tetra-antennary N-glycans remain high in prostate cancer cells after they have disseminated from the primary site and established metastatic lesions in bone.